U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
Go back to U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer| (AMEX: IVBIY) | Delayed: 19.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.48 | 52 Week High | $ | |||
| Open | $19.48 | 52 Week Low | $ | |||
| Day High | $19.48 | P/E | N/A | |||
| Day Low | $19.48 | EPS | $ | |||
| Volume | 1 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 724.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $724.87 | 52 Week High | $88.16 | |||
| Open | $724.87 | 52 Week Low | $67.88 | |||
| Day High | $724.87 | P/E | 167.79 | |||
| Day Low | $724.87 | EPS | $4.32 | |||
| Volume | 469 | |||||
